These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11773089)

  • 41. Study on mutations and antiretroviral therapy (SMART): preliminary results.
    Gianotti N; Moretti F; Tambussi G; Racca S; Presi S; Crucianelli R; Carrera P; Ferrari M; Lazzarin A
    Antivir Ther; 1999; 4 Suppl 3():65-9. PubMed ID: 16021873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.
    Call SA; Saag MS; Westfall AO; Raper JL; Pham SV; Tolson JM; Hellmann NS; Cloud GA; Johnson VA
    J Infect Dis; 2001 Feb; 183(3):401-8. PubMed ID: 11133371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance against reverse transcriptase inhibitors.
    O'Brien WA
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S185-92. PubMed ID: 10860904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
    Wirden M; Delaugerre C; Marcelin AG; Ktorza N; Ait Mohand H; Dominguez S; Schneider L; Ghosn J; Pauchard M; Costagliola D; Katlama C; Calvez V
    Antimicrob Agents Chemother; 2004 Feb; 48(2):644-7. PubMed ID: 14742228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human immunodeficiency virus drug susceptibility and resistance testing.
    Tobin NH; Frenkel LM
    Pediatr Infect Dis J; 2002 Jul; 21(7):681-3. PubMed ID: 12237603
    [No Abstract]   [Full Text] [Related]  

  • 47. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
    Adjé C; Cheingsong R; Roels TH; Maurice C; Djomand G; Verbiest W; Hertogs K; Larder B; Monga B; Peeters M; Eholie S; Bissagene E; Coulibaly M; Respess R; Wiktor SZ; Chorba T; Nkengasong JN;
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):501-6. PubMed ID: 11391173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates.
    Campo RE; Lichtenberger PN; Rosa I; Suarez G; Rivera FA; Rodriguez AE; Jayaweera DT; Wahlay NA; Kolber MA
    J Clin Microbiol; 2003 Jul; 41(7):3376-8. PubMed ID: 12843097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
    Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
    Harrigan PR; Salim M; Stammers DK; Wynhoven B; Brumme ZL; McKenna P; Larder B; Kemp SD
    J Virol; 2002 Jul; 76(13):6836-40. PubMed ID: 12050397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
    Hachiya A; Aizawa-Matsuoka S; Tanaka M; Takahashi Y; Ida S; Gatanaga H; Hirabayashi Y; Kojima A; Tatsumi M; Oka S
    Antimicrob Agents Chemother; 2001 Feb; 45(2):495-501. PubMed ID: 11158746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenotypic susceptibility to antiretrovirals among clades C, F, and B/F recombinant antiretroviral-naive HIV type 1 strains.
    Sucupira MC; Munerato P; Silveira J; Santos AF; Janini LM; Soares MA; Diaz RS
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):880-6. PubMed ID: 23398474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).
    García Lerma J; Schinazi RF; Juodawlkis AS; Soriano V; Lin Y; Tatti K; Rimland D; Folks TM; Heneine W
    Antimicrob Agents Chemother; 1999 Feb; 43(2):264-70. PubMed ID: 9925516
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.
    Miller V; de Béthune MP; Kober A; Stürmer M; Hertogs K; Pauwels R; Stoffels P; Staszewski S
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3123-9. PubMed ID: 9835502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure.
    Yang J; Geng W; Zhang M; Han X; Shang H
    J Basic Microbiol; 2014 Oct; 54(10):1120-5. PubMed ID: 24338739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
    Parkin N; Chappey C; Maroldo L; Bates M; Hellmann NS; Petropoulos CJ
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):128-36. PubMed ID: 12394790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.